Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.70
-5.4500-2.45%
Volume:344.92K
Turnover:75.51M
Market Cap:31.99B
PE:38.49
High:223.09
Open:220.30
Low:215.73
Close:222.15
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.62
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.65

Loading ...

Biogen is Maintained at Neutral by Wedbush

Dow Jones
·
Jul 30

Biogen price target lowered to $240 from $242 at RBC Capital

TIPRANKS
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth

Reuters
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Regeneron Q2 Revenue Beats on Higher Dupixent, Eylea HD Sales

Reuters
·
Jul 30

Agios Q2 Revenue Jumps on US Commercial Launch of Aqvesme

Reuters
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Biogen : TD Cowen Raises Target Price to $225 from $215

THOMSON REUTERS
·
Jul 30

Analysts’ Top Healthcare Picks: Icon (ICLR), Biogen (BIIB)

TIPRANKS
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Benzinga Earnings
·
Jul 30

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating

MT Newswires Live
·
Jul 30

Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214

MT Newswires Live
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 29

Biogen's Q2 Results Beat Boosted By Apellis Acquisition, Wedbush Says

MT Newswires Live
·
Jul 29

U.S. stock movers: Q2 revenue and earnings per share beat expectations, Biogen (BIIB.US) climbs over 5%

Stock News
·
Jul 29

Is Biogen (BIIB) Undervalued Following Its Q2 2026 Earnings?

Simply Wall St.
·
Jul 29